Weighted Average Number of Shares Outstanding, Basic of Intra-Cellular Therapies, Inc. from 31 Dec 2020 to 31 Dec 2024

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Intra-Cellular Therapies, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 Dec 2020 to 31 Dec 2024.
  • Intra-Cellular Therapies, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2024 was 103,131,017, a 7.6% increase year-over-year.
  • Intra-Cellular Therapies, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 103,131,017, a 7.6% increase from 2023.
  • Intra-Cellular Therapies, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 95,881,729, a 2% increase from 2022.
  • Intra-Cellular Therapies, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 94,046,670, a 16% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Intra-Cellular Therapies, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 103,131,017 +7,249,288 +7.6% 01 Oct 2024 31 Dec 2024 10-K 21 Feb 2025 2024 FY
Q3 2024 105,768,386 +9,625,303 +10% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2024 2024 Q3
Q2 2024 103,723,007 +7,774,944 +8.1% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 96,875,275 +1,740,581 +1.8% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 95,881,729 +1,835,059 +2% 01 Oct 2023 31 Dec 2023 10-K 21 Feb 2025 2024 FY
Q3 2023 96,143,083 +1,626,289 +1.7% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024 2024 Q3
Q2 2023 95,948,063 +1,662,946 +1.8% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 95,134,694 +2,530,404 +2.7% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 94,046,670 01 Oct 2022 31 Dec 2022 10-K 21 Feb 2025 2024 FY
Q3 2022 94,516,794 +13,162,070 +16% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 94,285,117 +13,055,329 +16% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 92,604,290 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q3 2021 81,354,724 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 81,229,788 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2

Intra-Cellular Therapies, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 103,131,017 +7,249,288 +7.6% 01 Jan 2024 31 Dec 2024 10-K 21 Feb 2025 2024 FY
2023 95,881,729 +1,835,059 +2% 01 Jan 2023 31 Dec 2023 10-K 21 Feb 2025 2024 FY
2022 94,046,670 +12,793,276 +16% 01 Jan 2022 31 Dec 2022 10-K 21 Feb 2025 2024 FY
2021 81,253,394 +10,888,594 +15% 01 Jan 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
2020 70,364,800 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.